Soligenix Goodwill and Intangible Assets 2010-2025 | SNGX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Soligenix goodwill and intangible assets from 2010 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Soligenix goodwill and intangible assets from 2010 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$233.7B
Amgen (AMGN)	$153.4B
Gilead Sciences (GILD)	$148.9B
Vertex Pharmaceuticals (VRTX)	$99.4B
Bristol Myers Squibb (BMY)	$94.7B
CSL (CSLLY)	$83.8B
GSK (GSK)	$77.9B
Regeneron Pharmaceuticals (REGN)	$59B
Alnylam Pharmaceuticals (ALNY)	$56.4B
Argenex SE (ARGX)	$39B
BioNTech SE (BNTX)	$26.7B
Insmed (INSM)	$25.8B
Royalty Pharma (RPRX)	$20.2B
Biogen (BIIB)	$18.9B
Incyte (INCY)	$15.9B
Illumina (ILMN)	$15B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$14B
Ascendis Pharma (ASND)	$12B
BioMarin Pharmaceutical (BMRN)	$10.9B
QIAGEN (QGEN)	$10.9B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.2B
Moderna (MRNA)	$10B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.3B
Exact Sciences (EXAS)	$7.9B
Halozyme Therapeutics (HALO)	$7.9B
Roivant Sciences (ROIV)	$7.9B